This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...

PTHS and Meridian Mounds will take the court on Friday, Feb. 6 at 6 p.m. CT. Don't miss out on any of the action with NFHS Network.

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. Received written feedback from the US FDA for NNZ-2591 development in both HIE and ...

Chromocell Therapeutics Corp (NASDAQ:CHRO) CEO Francis Knuettel II has recently made a purchase of the company's common stock, ...

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. The post Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical ...

More news: Shares in Neuren Pharmaceuticals fell sharply in morning trade despite the company receiving meeting feedback from ...

Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Pelthos Therapeutics today and set a price target of $57.00. According to TipRanks, Aschoff is an analyst with an average return of -20.3% ...

Stifel Nicolaus analyst David Grossman maintained a Buy rating on OptimizeRx yesterday and set a price target of $21.00. The company’s shares closed last Friday at $12.42, close to its 52-week high of ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.